Key facts
- This page summarizes Daniel L. Kisner's Form 4 filing for Zynerba Pharmaceuticals, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2022, 21:53.
Daniel L. Kisner - 14 Jun 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Jun 2022
- Net transaction value
- -$40.4
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2022, 21:53:28 UTC
- Prior SEC filing
- 03 Jun 2022
- Next SEC filing
- 17 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Albert P. Parker, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel L. Kisner filed Form 4 for Zynerba Pharmaceuticals, Inc. on 16 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2022.
- Current net transaction value: -$40.4.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZYNE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +23,109
- Change %
- +462%
- Price
- $0.000000
- Shares after
- 28,109
- Date
- 14 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
ZYNE
transaction
Common Stock
Sale
- Transaction value
- $40.4
- Shares
- -40
- Change %
- -0.14%
- Price
- $1.01
- Shares after
- 28,069
- Date
- 14 Jun 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYNE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +34,663
- Change %
- Price
- $0.000000
- Shares after
- 34,663
- Date
- 14 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,663
- Exercise price
- $1.01
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.
Footnote F2
This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
Footnote F3
The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.